A comprehensive view of Janssen Pharmaceutical Companies. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Tissue & Hygiene Market Intelligence Service.
FDA Approves Innovative Treatment for Pulmonary Arterial Hypertension, Expanding Pharmaceutical Company's PAH Portfolio
Published:
March 23, 2024
by Industry Intelligence Inc.
|
U.S. FDA Approves OPSYNVI® (macitentan and tadalafil) as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension (PAH)
Published:
March 22, 2024
by Janssen Pharmaceutical Companies
|
Janssen underscores its commitment to bring targeted treatment options for EGFR-mutated Lung Cancer, despite low five-year survival rates for patients
Published:
March 21, 2024
by Industry Intelligence Inc.
|
U.S. FDA Approves EDURANT® PED (rilpivirine) for Certain Pediatric Patients Living with HIV-1
Published:
March 19, 2024
by Janssen Pharmaceutical Companies
|
Janssen Pharmaceutical targets innovative therapies for major diseases, aiming to transform patient care in AMD, multiple myeloma, and lung cancer
Published:
March 19, 2024
by Industry Intelligence Inc.
|
Ask us about our Tissue & Hygiene market view